← Back to Search

Smartwatch Reminders for Alzheimer's Disease

N/A

Waitlist Available

Research Sponsored by University of Minnesota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

a physician diagnosis of early-stage Alzheimer's disease or mild-to-moderate cognitive impairment

21 years of age or over

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 3-, and 6-months

Awards & highlights

Study Summary

This trial aims to help people with memory impairment by providing them with a smartwatch that will remind them of people's faces and names.

Who is the study for?

This trial is for English-speaking adults over 21 with early-stage Alzheimer's or mild-to-moderate cognitive impairment, without serious mental illness. Participants must assist someone with memory loss (care partners) and plan to stay local for at least 6 months.Check my eligibility

What is being tested?

The study tests a Smartwatch Reminder system designed to help people with memory concerns by providing information about familiar faces and names. The goal is to see if it improves social interaction and quality of life.See study design

What are the potential side effects?

Since the intervention involves using technology rather than medication, traditional side effects are not expected; however, potential issues may include privacy concerns or reliance on the device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with early-stage Alzheimer's or mild-to-moderate cognitive issues.

Select...

I am 21 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 3-, and 6-months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 3-, and 6-months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3-, and 6-months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in PWMC Quality of Life

Change in PWMC Social Interaction Frequency

Change in PWMC Social Interaction Quality

Secondary outcome measures

Change in Care Partner Depression

Change in Care Partner Loneliness in Relationship

Change in Care Partner Psychosocial Well-Being

+10 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention GroupExperimental Treatment1 Intervention

The PWMC and Care partner in this group will receive the SR. The project will provide a smartwatch and smartphone for the dyads in the study. All others (family, friends, etc.) will be able to download a smartphone app from an online store. Instructional material will be created to show the suggested information that can be entered into the app. Care partners and PWMC are administered surveys at baseline, 3 months and 6 months following enrollment.

Group II: Attention Control GroupActive Control1 Intervention

Care partners are administered surveys at baseline, 3 months and 6 months following enrollment. The attention control group will receive a contact call from one of the researchers 3-months and 6-months after enrollment. Based on our prior experience, PWMC and care partners in an attention control group will often seek information and psychosocial support during these calls. We will provide free information resources (e.g., brochures or websites of the Alzheimer's Association) at that time.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Smartwatch Reminder (SR) system

2022

N/A

~170

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Advanced Medical ElectronicsOTHER

5 Previous Clinical Trials

269 Total Patients Enrolled

3 Trials studying Dementia

137 Patients Enrolled for Dementia

Brown UniversityOTHER

456 Previous Clinical Trials

558,192 Total Patients Enrolled

19 Trials studying Dementia

208,157 Patients Enrolled for Dementia

University of MichiganOTHER

1,797 Previous Clinical Trials

6,377,896 Total Patients Enrolled

9 Trials studying Dementia

1,554 Patients Enrolled for Dementia

Media Library

Intervention Group Clinical Trial Eligibility Overview. Trial Name: NCT04700540 — N/A

Dementia Research Study Groups: Attention Control Group, Intervention Group

Dementia Clinical Trial 2023: Intervention Group Highlights & Side Effects. Trial Name: NCT04700540 — N/A

Intervention Group 2023 Treatment Timeline for Medical Study. Trial Name: NCT04700540 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants currently being welcomed into this clinical trial?

"That is correct. According to the information on clinicaltrials.gov, this trial has been recruiting since September 1st 2022 and requires 200 patients from one specific site. The details of the study were last updated on September 19th 2022."

Answered by AI

What is the scale of this research project in terms of patient participation?

"Absolutely, clinicaltrials.gov indicates that this experiment is currently recruiting patients; it was first published on September 1st 2022 and its most recent update was made on the 19th of September. The trial requires 200 participants to be enrolled at a single site."

Answered by AI

What objectives does this research endeavor aspire to achieve?

"This 6-month study will assess changes in Patient With Memory Complication Quality of Life. Supplementary endpoints encompass Transformation in Care Partner Loneliness, as gauged by the UCLA Lonliness Scale (20 to 80 points; higher scores show amplified isolation), Alteration in Care Partner Psychosocial Wellbeing measured with Eriksonian's 11-item Psychosocial Stage Inventory (11 to 55 marks; larger values denote improved well-being) and Variance in Negative Health Transitions evaluated via a one item questionnaire related to modification of living or care state and mortality rates."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Mobile Informatics Solution to Aid in Memory

Jude Mikal, PhD 2022. "A Mobile Informatics Solution to Aid in Memory". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04700540.